Randomized Control Trial of Vivex Tissue for Accelerated Wound Healing Following Penile Prosthesis Placement With Follow-up

Status: Terminated
Location: See location...
Intervention Type: Biological, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on men undergoing penile implant surgery for the first time. The patients are randomized in a 2:1 ratio of active to sham treatment groups.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 30
Maximum Age: 70
Healthy Volunteers: t
View:

• The patient must be willing and able to provide informed consent

• The patient is a male between \>/= 30 and =/\< 70 years of age

• The patient has ED based of International Index of Erectile Dysfunction (IIEF) scores

• The patient has been in a stable relationship for over 3 months prior to enrollment

• A minimum of 2 sexual attempts per month for at least one month prior to enrollment - as documented by IIEF

• The patient is suffering from erectile dysfunction and undergoing penile implant surgery for the first time

• IIEF-EF score between 16 and 25

• Testosterone level 300-1000 ng/dL within 1 month prior to enrollment

• A1C level \</= 7% within 1 month prior to enrollment

Locations
United States
Georgia
Atlanta Cosmetic Urology
Atlanta
Time Frame
Start Date: 2022-01-03
Completion Date: 2023-12-30
Participants
Target number of participants: 32
Treatments
Experimental: Viagenex Max
VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.
Active_comparator: Standard of care
Hibiclens wash will be performed.
Related Therapeutic Areas
Sponsors
Leads: VIVEX Biologics, Inc.

This content was sourced from clinicaltrials.gov